Compare BFC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | MPLT |
|---|---|---|
| Founded | 1894 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | 2025 |
| Metric | BFC | MPLT |
|---|---|---|
| Price | $153.63 | $13.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $157.00 | $32.67 |
| AVG Volume (30 Days) | 54.4K | ★ 568.5K |
| Earning Date | 04-16-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | 11.23 | ★ 82.39 |
| EPS | ★ 3.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.67 | N/A |
| Revenue Next Year | $2.01 | N/A |
| P/E Ratio | $37.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $119.08 | $9.10 |
| 52 Week High | $159.10 | $40.43 |
| Indicator | BFC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 39.69 |
| Support Level | $149.89 | $12.24 |
| Resistance Level | $159.10 | $20.20 |
| Average True Range (ATR) | 3.39 | 0.98 |
| MACD | -0.53 | 0.92 |
| Stochastic Oscillator | 52.09 | 75.51 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.